KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $332.9 million.

  • Vertex Pharmaceuticals' Change in Accured Expenses rose 9513.48% to $332.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.5 million, marking a year-over-year increase of 2904.14%. This contributed to the annual value of $212.9 million for FY2024, which is 5041.92% down from last year.
  • According to the latest figures from Q3 2025, Vertex Pharmaceuticals' Change in Accured Expenses is $332.9 million, which was up 9513.48% from $166.6 million recorded in Q2 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Change in Accured Expenses peaked at $485.5 million during Q2 2022, and registered a low of -$437.8 million during Q4 2022.
  • Its 5-year average for Change in Accured Expenses is $107.3 million, with a median of $153.0 million in 2021.
  • Data for Vertex Pharmaceuticals' Change in Accured Expenses shows a peak YoY increase of 116703.3% (in 2022) and a maximum YoY decrease of 95507.81% (in 2022) over the last 5 years.
  • Over the past 5 years, Vertex Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $51.2 million in 2021, then crashed by 955.08% to -$437.8 million in 2022, then rose by 18.52% to -$356.7 million in 2023, then rose by 10.26% to -$320.1 million in 2024, then skyrocketed by 204.0% to $332.9 million in 2025.
  • Its Change in Accured Expenses stands at $332.9 million for Q3 2025, versus $166.6 million for Q2 2025 and $48.1 million for Q1 2025.